---
title: "CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293485845.md"
description: "Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.Original document: Curis, Inc. [CRIS] Slides Release — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-22T14:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293485845.md)
  - [en](https://longbridge.com/en/news/293485845.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293485845.md)
generator: "portal-rs"
---

# CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials

Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.

Original document: Curis, Inc. \[CRIS\] Slides Release — Jul. 22 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

- [Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks](https://longbridge.com/en/news/296014406.md)
- [CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding](https://longbridge.com/en/news/293464781.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [20:00 ETAbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma](https://longbridge.com/en/news/296036085.md)
- [Curis notifies press release availability on positive emavusertib update](https://longbridge.com/en/news/293462544.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**